Systematic review finds hesperidin supplementation reduces inflammation biomarkers in adults, suggesting health benefits.
The purpose of this systematic review and meta-analysis was to investigate the effects of hesperidin supplementation on inflammatory and oxidative stress biomarkers in human adults. A systematic literature search was conducted in the PubMed, EMBASE and Cochrane central Register of Controlled Trials (CENTRAL) from inception to 4 January 2025 to identify eligible RCT studies. Ten RCTs with a total of 532 participants were included. The results indicated that hesperidin supplementation significantly reduced the serum levels of CRP/hs-CRP (SMD: -0.43, 95% CI: -0.71, -0.15, P=0.002) and TNF-α (SMD: -0.51, 95% CI: -0.95, -0.07, P=0.02) in adults, while no significant beneficial effect of hesperidin on IL-6 was observed (SMD: -0.25, 95% CI: -0.52, 0.01, P=0.06). In addition, hesperidin intake showed beneficial impact on IL-6 level in patients with diseases (type 2 diabetes and myocardial infarction) (SMD: -0.38, 95% CI: -0.72, -0.04, P=0.03) yet not in healthy adults without diagnosed diseases. Our findings demonstrated that hesperidin supplementation could lower the serum levels of CRP/hs-CRP and TNF-α in adults.
No takes yet. Share an insight, caveat, or question.
Ouyang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: